You can buy or sell BPTH and other stocks, options, ETFs, and crypto commission-free!
Bio-Path Holdings, Inc. Common Stock, also called Bio-Path Holdings, is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Read More Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
52 Week High
52 Week Low
Seeking AlphaMay 16
Bio-Path Holdings, Inc. CEO Peter Nielsen on Q1 2019 Results - Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q1 2019 Earnings Conference Call May 16, 2019 8:30 AM ET Company Participants Peter Nielsen - President, Chief Executive Officer Anthony Price - Vice President, Finance and Accounting Will O’Connor - Stern Investor Relations Conference Call Participants Laura Engle - Stonegate Capital Partners Operator Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings full year 2018 earnings conference call. At this time, all participants are in a listen-only m...
Yahoo FinanceApr 29
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)
BELLAIRE, TX / ACCESSWIRE / April 29, 2019 / Bio-Path Holdings, Inc. (BPTH). The full report can be accessed by clicking on the following link: http://stonegateinc.com/reports/BPTH%20Update%20April%202019%20Final%20v4.pdf Company Description Bio-Path Holdings, Inc. (Bio-Path) is a clinical stage biotechnology company that focuses on developing nucleic acid cancer therapeutics using its proprietary nanoparticle RNAi antisense technology called DNAbilize®. This technology safely distributes nucleic acid b...
-$0.89 per share